PALB2 and pancreatic neoplasm: In several prior retrospective studies, it has been suggested that overall survival is improved when platinum-based therapy is administered to patients with pancreatic cancer harbouring germline BRCA or PALB2 mutations.18,19,24 However, less is known about the objective response rate to these drugs in this subgroup, and this knowledge may help guide treatment decisions in the neoadjuvant setting and for symptomatic patients, as well as inform clinical trial design for this group.